Initial Steps

Before initiating any regulatory process, pharmaceutical companies must engage with the TITCK to understand specific requirements. Here are the key steps involved in this engagement:

Step 2.1: Pre-Submission Meetings

Prior to submitting an application for marketing authorization, companies are encouraged to request a pre-submission meeting with TITCK. This meeting serves as a platform to clarify regulatory expectations and gather insights about the required documentation.

• Prepare a Briefing Document: This document should outline the product’s intended use, manufacturing process, and relevant clinical data.
• Understand Regulatory Requirements: During the meeting, actively inquire about the specific requirements for the dossier and any anticipated compliance challenges.

Step 2.2: Setting up Local Representation

Foreign companies looking to market their products in Turkey must appoint a local representative, which can be a person or an organization with established ties to the Turkey market. This representative will serve as the liaison between TITCK and the applicant.

• Select a Competent Partner: Choose a local entity with expertise in regulatory affairs.
• Ensure Documentation: The local representative should maintain all communication records with TITCK and facilitate documentation submissions.

3. Dossier Preparation for Marketing Authorization

The preparation of the regulatory dossier is the next critical step in obtaining marketing authorization. Each section requires meticulous attention to detail, as TITCK conducts thorough evaluations. The structure of the dossier typically follows the Common Technical Document (CTD) format, comprising several modules.

Step 3.1: Module 1 – Administrative Information

This module includes critical information such as the application form, details of the applicant, and a summary of the product. A well-prepared Module 1 ensures that TITCK can easily verify applicant details and the product’s intended use.

Step 3.2: Module 2 – Summaries

Module 2 includes summaries of the quality, non-clinical, and clinical data for the product. This section must provide a concise overview and justification for the proposed medicinal product, demonstrating how it fulfills the medical need.

Step 3.3: Module 3 – Quality

Data pertaining to the product’s quality is found in Module 3. This section must include comprehensive information about:

• Composition and formulation of the drug product
• Manufacturing processes
• Stability data
• GMP compliance documentation

Step 3.4: Module 4 – Non-Clinical Study Reports

Module 4 encompasses non-clinical studies that demonstrate the pharmacological and toxicological profile of the medicinal product. It is critical to provide adequate justification for the choice of study methodologies and any interpretations of results.

Step 3.5: Module 5 – Clinical Study Reports

This module contains detailed reports of clinical studies conducted. Companies should ensure that all trials comply with the ICH-GCP guidelines. Submission must include:

• Ethical approvals
• Informed consent documentation
• Data analysis and conclusions drawn from the clinical studies

4. Submission Process of Dossier to TITCK

Once the dossier is prepared, the next step is the actual submission to TITCK. The submission process involves specific protocols and timelines that must be adhered to ensure a smooth review.

Step 4.1: Electronic Submission Requirements

TITCK mandates that all submissions be made electronically through the Online Application System (OAS). This system requires the signing of an electronic submission agreement and relevant fees to be processed prior to dossier filing.

Step 4.2: Payment of Fees

Upon submission, applicants are required to pay a specific fee for the marketing authorization review. Make sure to check the latest fee schedule published on the TITCK website, as fees could be adjusted annually.

Step 4.3: Acknowledgment of Receipt

Within a predetermined timeframe, TITCK will issue an acknowledgment receipt confirming that the application has been received. This acknowledgment is critical for tracking the progress of your application through the review process.

5. Review Process and Expectations from TITCK

The review process is an essential phase where the submitted dossier is critically assessed for compliance with regulatory standards. The average review timeline depends on the complexity of the submission but generally lasts between 180 to 270 days.

Step 5.1: Evaluation of Quality, Safety, and Efficacy

During this phase, TITCK will evaluate the submitted data to determine whether the product meets predefined criteria concerning safety, efficacy, and quality. The agency may also refer to external experts for further insights.

Step 5.2: Communication During Review

TITCK typically communicates with the applicant throughout the review process, which can include requests for additional information or clarifications. It is essential to respond promptly to any inquiries to prevent delays.

Step 5.3: Approval or Rejection Decision

Upon completion of the review, TITCK will either approve or reject the application. If the application is rejected, the applicant will receive a detailed explanation, allowing for resubmission. Approved products will be assigned a marketing authorization number and officially listed.

6. Post-Marketing Surveillance and Compliance

Once a product has been authorized for marketing, compliance with post-marketing surveillance is paramount. This ensures ongoing product safety and efficacy through structured pharmacovigilance practices.

Step 6.1: Establishing a Pharmacovigilance System

Pharmaceutical companies must set up a robust pharmacovigilance system to monitor the safety of their products once they are on the market. This involves:

• Report adverse events and any safety concerns immediately to TITCK
• Regularly review and update risk management plans as new data emerges

Step 6.2: Compliance Inspections

TITCK conducts regular inspections to ensure compliance with regulatory standards. Companies should be prepared for announced and unannounced visits, which assess aspects such as:

• Good Manufacturing Practices (GMP) compliance
• Quality control processes
• Documentation practices

Step 6.3: Reporting Obligations

Regular reporting is required to maintain authorization, including the submission of annual safety reports, updates on manufacturing changes, and any labels updates. Ensure compliance through systematic record-keeping and updates to the agency.

Conclusion: Navigating the Turkish Regulatory Landscape

Understanding and navigating the Turkish Medicines and Medical Devices Agency (TITCK) regulatory process is crucial for pharmaceutical companies aiming to enter or operate in Turkey. By following the outlined steps from initial engagement through submission, review, and post-marketing obligations, companies can facilitate a successful regulatory journey.

For comprehensive and updated information regarding the regulatory framework, refer to the official [TITCK website](https://www.titck.gov.tr). It is advisable to stay informed on changes in regulations, as these can significantly impact the pharmaceutical regulatory landscape in Turkey.